logo.jpg
CYBIN Closes Acquisition of Adelia Therapeutics; Bolsters Scientific Team and Grows IP Portfolio to 7 Patent Filings
December 14, 2020 08:07 ET | Cybin Inc.
--Newly acquired novel psychedelic molecules diversify Cybin’s development portfolio, providing access to multiple future indications-- --Adelia brings a range of technologies related to novel...
W2Email Logo.jpg
Way2Grow (W2G) Biopharma Company Receives Health Canada Standard Cultivation License, Processing License and Medical Sales License
December 08, 2020 08:17 ET | Way2Grow Nurseries
OSOYOOS, British Columbia, Dec. 08, 2020 (GLOBE NEWSWIRE) -- via CannabisNewsWire – Way2Grow Nurseries (“Way2Grow” or “W2G”), a privately owned biopharma company, is pleased to announce that it has...
MacroGenics-Logo-(transparent-background).png
MacroGenics and EVERSANA Announce Agreement to Support the Potential Launch and Commercialization of Margetuximab
November 30, 2020 16:30 ET | MacroGenics, Inc.
MacroGenics accesses EVERSANA’s full suite of commercial services for which both parties share expensesEVERSANA may earn revenue share payments over five years subject to predefined capMacroGenics’...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Achievement of $25 Million in Milestones Related to Retifanlimab Collaboration with Incyte
November 30, 2020 07:30 ET | MacroGenics, Inc.
ROCKVILLE, MD, Nov. 30, 2020 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
pcsa.jpg
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
November 16, 2020 12:48 ET | Processa Pharmaceuticals Inc.
HANOVER, MD., Nov. 16, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conferences
November 09, 2020 17:00 ET | MacroGenics, Inc.
ROCKVILLE, MD, Nov. 09, 2020 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Date of Third Quarter 2020 Financial Results Conference Call
October 28, 2020 16:30 ET | MacroGenics, Inc.
ROCKVILLE, MD, Oct. 28, 2020 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces MGC018 Publication in Molecular Cancer Therapeutics
September 23, 2020 07:15 ET | MacroGenics, Inc.
Manuscript describes preclinical development of MGC018Phase 1 dose expansion trial evaluating MGC018 in patients with mCRPC, TNBC and NSCLC is currently recruiting patients ROCKVILLE, MD,...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Publication of Flotetuzumab Interim Phase 1/2 Clinical Trial Results in Blood
September 22, 2020 16:30 ET | MacroGenics, Inc.
ROCKVILLE, MD, Sept. 22, 2020 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Development Milestone Achieved in Retifanlimab (MGA012) Collaboration with Incyte
September 21, 2020 07:30 ET | MacroGenics, Inc.
$15 Million milestone triggered by initiation of Phase 3 clinical trial in NSCLC by Incyte ROCKVILLE, MD, Sept. 21, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage...